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Validation of Accelerometer Prediction Equations in Children with Chronic Disease 
Abstract: 
Purpose:  To assess the criterion validity of existing accelerometer-based energy 
expenditure (EE) prediction equations among children with chronic conditions, and to 
develop new prediction equations. 
Methods: Children with congenital heart disease (CHD), cystic fibrosis (CF), 
dermatomyositis (JDM), juvenile arthritis (JA), inherited muscle disease (IMD), and 
haemophilia (HE), completed 7 tasks while EE was measured using indirect calorimetry 
with counts determined by accelerometer. Agreement between EE predicted and 
measured EE was assessed. Disease-specific equations and cut points were developed and 
cross-validated.  
Results: 196 subjects participated. One participant dropped out prior to testing due to 
time constraints, 15 CHD, 32 CF, 31 JDM, 31 JA, 30 IMD, 28 HE and 29 healthy 
controls completed the study. Agreement between predicted and measured EE varied 
across disease group and ranged (ICC) 0.13-0.46. Disease specific prediction equations 
exhibited a range of results (ICC 0.62 to ICC 0.88) (SE 0.45-0.78). 
Conclusion:  Poor agreement was demonstrated using current prediction equations in 
children with chronic conditions. Disease-specific equations and cut points were 
developed.  
Acknowledgements: This study was funded with a grant from the Canadian Institute of 
Health Research (# 167391/CIHR).  The study authors have no conflicts of interest to 
report.   
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Introduction 
 Physical activity participation at moderate and vigorous levels has been shown to have 
an important protective effect on cardiovascular and metabolic profiles in healthy 
children that may prevent chronic illness later in adulthood (4, 17). The role of physical 
activity in children with chronic illness may have an even more substantial and wide-
ranging health impact—from improving cardiometabolic profiles to improving physical 
function and limiting long-term disability (16). For example, accurate determination of 
physical activity related energy expenditure could allow for the better clinical 
management of diseases such as Cystic Fibrosis or Duchene’s muscular dystrophy where 
nutritional considerations and energy requirements play a critical role in health outcome 
(37, 48). Further, the ability to accurately quantify physical activity dose (e.g. time spent 
in light, moderate and vigorous physical activity) in children with chronic conditions in 
order to prescribe a dose that confers benefit rather than harm is also of great importance. 
The true effect of physical activity level and role of physical activity related energy 
expenditure on health outcome in children with chronic conditions is currently unclear 
due, in part, to the lack of a precise measure of physical activity (16, 27, 41).   
Objective methods to determine physical activity levels in children may provide more 
accurate and unbiased estimates compared to subjective measurement methods.  One 
objective method that has gained popularity, accelerometry, has demonstrated superior 
validity and reliability when compared to subjective methods such as self-report (2, 39). 
Accelerometers have proven to be reliable and accurate in healthy children and 
adolescents when compared with doubly labelled water, calorimety and direct 
observation (22, 25, 45).   Raw signals related to change in velocity over time (m/s2) are 
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collected over a designated period of time (epoch) and are converted into a unit-less 
index referred to as a count.  Prediction equations are applied to convert counts into more 
physiologically meaningful indices of energy expenditure such as a metabolic equivalent 
(MET).  Additionally, cut-point values enabling the relationship between counts and 
physical activity intensity to be established have also been developed (45).  These 
equations and cut-point estimates have been validated for use in healthy children but not 
in those with chronic conditions. 
Prediction equations and cut-point estimates developed to provide more meaningful 
indices of energy expenditure or physical activity level from accelerometer counts in 
healthy children may not be accurate in children with chronic conditions.  Inaccuracies 
may arise from differences in resting metabolic rates, economy of motion, movement 
biomechanics, and energy cost of breathing in children with chronic conditions (36, 41). 
For example, a longitudinal study of changes in walking related energy expenditure in 
boys with Duchenne’s reported increases in energy expenditure with a decrease in 
comfortable walking distance (8). Boys who were older in age (>8years) had the highest 
increases in walking energy expenditure in comparison to younger boys, a finding that is 
opposite of what occurs in typically developed children(8). Children with disease often 
have inherent physiological or biomechanical differences from healthy children (gait 
deficiencies or metabolic abnormalities) that require them to work at a higher energy 
level to complete the same task (16, 18, 22, 36). For example, a recent gait analysis study 
of 36 children diagnosed with polyarticular arthritis revealed significant differences in 
walking mechanics including: slower walking speeds, a shorter stride length, reduced hip 
and knee extension, tilted pelvis and improper foot mechanics when compared to healthy 
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controls(23). These changes may lead to a higher energy cost of locomotion; such 
differences may not be accounted for by the currently available prediction equations and 
cut-point estimates and could produce significant bias in determining energy expenditure 
or activity levels if used in their current form. 
 Objective tools to measure physical activity in children with chronic conditions are 
needed to accurately determine the relationship between energy expenditure, activity 
level and health outcomes in clinical populations. Therefore the aim of this study was to 
determine if the current prediction equations used to transform accelerometer counts into 
units of energy expenditure are valid in children with chronic conditions. A secondary 
aim of this study was to perform exploratory analyses in order to determine new 
prediction equations and cut-point estimates should the current equations not be accurate 
for use in children with a chronic disease.  
Methods 
 A total of 167 subjects aged 7 to 18 years with a diagnosis of either: juvenile arthritis 
(JA), juvenile dermatomyositis (JDM), moderate or severe haemophilia (HE)A or B (up 
to 5% clotting factor), muscular dystrophinopathies (Beckers, Duchenes or other 
inherited muscle disease; IMD), cystic fibrosis (CF), or congenital heart disease (CHD) 
who had undergone a heart repair (Fontan repair or Tetrology of Fallot repair) were 
approached to participate in the study with the approval from the research ethics boards 
representing three pediatric teritiary care hospitals located in North America and Europe. 
In addition, 29 healthy children, identified from study advertisements posted on internal 
hospital websites and newsletters, were recruited from the same centres. Children were 
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excluded if they were on medication that would affect the heart-rate response to exercise, 
such as beta-blockers, or if they were unable to ambulate or unable to cooperate with the 
testing procedures.  Written informed consent and assent were collected from each 
guardian/subject in accordance to the guidelines of the ethics boards of the participating 
centers. 
Exercise Testing 
Each 2-hour testing session consisted of anthropometric measures, pulmonary function 
testing and three energy expenditure protocols: resting energy expenditure (REE), 
activities of daily living and exercise.  Subjects were asked to abstain from eating or 
drinking anything but water for 2 hours prior to their appointment for more accurate 
determination of REE (31, 34, 35). In order to allow for the comparison of our study 
population with other clinical populations, each subject completed a number of 
questionnaires pertaining to their physical function and quality of life.  All subjects 
underwent a familiarization session in which they were introduced to all equipment and 
were given instructions on how to complete each task.   
Exercise Testing Procedures 
At each session, height (Harpendum Stadiometer, London, UK) and weight (SR555 
Stand-on Scale System, SR Instruments, Tonawanda, NY) were measured to the nearest 
0.1 cm and 0.1 kg, respectively, with subjects wearing light clothing and no shoes. BMI 
was calculated as (kg/m2) with BMI percentile determined for each subject (21, 29). 
Skinfold measures were taken at the triceps, biceps, subscapular and suprailiac locations 
with the sum of skinfolds (mm) determined.  REE was measured for 20 minutes using 
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either a K4B2 (Cosmed, Albano Liziale, Rome) or Cortex Metamax (Cortex Metamax, 
CORTEX Biophysik GmbH, Leipzig Germany) while the subject was resting quietly, but 
awake, in the supine position (31, 34, 35). Subjects then completed a series of 7 tasks to 
represent a broad spectrum of energy expenditure intensities ranging from those 
associated with activities of daily living to moderate and vigorous exercise.  Tasks 
consisted of 6 minutes each of computer work, sweeping, over-ground walking at a self-
selected pace, stair stepping and 3 treadmill walking tasks.  In order to account for a wide 
variability in physical function level in our subjects, two different treadmill protocols 
were used.  A low and high function treadmill walking protocol was each determined 
from the 6-minute self-selected walking task.  Subjects who averaged a walking pace of 
≥3.5 km/hr completed the high function treadmill protocol of 2.0 km/hr, 3.5 km/hr, 6.0 
km/hr and those in the low function protocol completed a treadmill protocol of 1.0 km/hr, 
2.0 km/hr, and 3.5 km/hr.   
Outcomes 
Indirect Calorimetry: Expired gases were collected during each task using a portable 
metabolic cart (K4b2 in North America or a Cortex Metamax in Europe). Prior to study 
initiation the inter-unit reliability was established and no correction factor was necessary 
given the high level of agreement, with an Intraclass Correlation Coefficient (ICC) of 
0.98 (Confidence Interval 0.76-0.99) between the two metabolic systems. Oxygen uptake 
(VO2) and carbon dioxide production (VCO2) were recorded on a breath-by-breath basis 
and were averaged at 15-second intervals. Prior to each test the equipment was calibrated 
using standard protocols. Energy expenditure (J/kg/min) was calculated according to the 
de Weir equations (47). REE was calculated by taking the average of the last 10 minutes 
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of the values recorded by the metabolic cart during the 20 minute resting task. Activity 
Energy Expenditure (AEE) was calculated using the equation AEE = Total Energy 
Expenditure (TEE) – measured REE (32, 33). Metabolic equivalents (TEE/REE) were 
also determined for each activity.  
Accelerometry:  Both the Actical (Mini Mitter, Co) and Actigraph 7164 (Actigraph, LLC) 
accelerometers were chosen to measure acceleration activity counts based on their use in 
national studies of health indices (e.g. National Health and Nutritional Examination 
Survey and Canadian Healthy Measures Survey). The Actical is an omni-directional 
monitor with a sampling frequency of 32 Hz and sensitivity of 0.01 g. Actigraph is a 
unidirectional monitor with a sampling frequency of 10 Hz and sensitivity of 0.05-2.0 g 
(10).  
The two different accelerometer models, Actical and Actigraph, were placed on the right 
hip at the midaxillary line of the superior iliac crest using an elastic belt. The sampling 
rate was set to 15-second epochs for both devices. Prior to the initiation of this study, 
inter-monitor reliability was assessed and excellent agreement was established for all of 
the accelerometers distributed between the North American and European sites with 
ICC’s ranging from 0.98-0.99 (Confidence Interval, 0.88-1.0).  Heart rate measured beat 
by beat was determined by a heart rate monitor (Polar Vantage XL 650i, Polar 
Instruments, Kemplele, Finland) for each task with data averaged each 15 seconds and 
downloaded for analysis.  
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Questionnaires:  
Subjects completed the Child Health Assessment Questionnaire (CHAQ)(38), the Quality 
of My Life Scale (QOML)(26), the Pediatric Quality of Life Scale (PedsQL)(20, 46), the 
Physical Activity Questionnaire for Children and Adolescents (28) and the Tanner 
Staging Questionnaire(15).  The CHAQ consists of questions from 8 functional domains 
comprising eating, dressing and grooming, walking, arising, hygiene, reach, activities, 
and grip. A summary score is given based on the 8 functional activity domains and is 
rated on a 3-point scale (where 0 indicates no limitations and 3 indicates severe 
limitations).  Overall quality of life (QOL) and health related quality of life (HRQOL) 
were measured by the QOML on separate 10 cm visual analog scale with lower scores 
indicating worse QOL/HRQOL and higher scores indicating better QOL/HRQOL. The 
PedsQL generic core, validated in childhood disease, consists of 23 items from 4 
different dimensions related to physical, emotional, social and school functioning (46).  
Items are scaled on a 5-point ordinal scale with 0 indicating never and 4 indicating almost 
always.  Items were reverse scored and transformed into a 100 point scale, a total score 
was derived by taking the sum of all of the items and dividing by the total number of 
completed items (out of 23) with higher scores indicating better quality of life(46). 
Pubertal stage was determined using a self-report Tanner staging method (15) . Pain and 
illness severity were determined using a10 cm visual analog scale from the CHAQ 
questionnaire.    
Data management 
Data from the portable metabolic carts and from the 2 accelerometers were all imported 
into Microsoft excel and merged with the count data from the accelerometers for each 
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task.  A special programming script was written in Python (www.python.org) and run to 
merge all of the subject accelerometer and metabolic data into one summary datasheet. In 
order to determine agreement between predicted and measured EE we averaged the 
accelerometer and metabolic data over the last 2 minutes of each of the task in order to 
capture steady state similar to the protocols of the original validation studies(22, 32, 33).  
For the purpose of the exploratory analysis, metabolic and accelerometer data were kept 
in an as per monitor format.  The as per monitor data format was used for analysis 
purposes and kept the metabolic and accelerometer data in its’ original 15 second format 
with the exception of subtracting out the last 30 seconds of each subjects’ data to allow 
for transitions and timing issues between tasks. Data in this format were used to preserve 
data integrity and to encourage a more realistic picture of physical activity (6, 40).   All 
individual items and scores for each of the questionnaires were entered into a Filemaker 
Pro database (FilemakerPro V., Filemaker, Inc., Santa Clara, Ca). Finally, all data were 
imported into SAS 9.3 (SAS Inc, Cary, N.C.) for further statistical analyses. 
Statistical Analysis  
Patient characteristics and questionnaire scoring were summarized using descriptive 
statistics (e.g. mean, range and standard deviations). Groups were compared using 
Analysis of Variance; subsequent pairwise comparisons were corrected for multiple 
testing using Tukey’s HSD. The primary objective of this study was assessed by 
determining the criterion validity of estimated EE, calculated using manufacturer-
specified accelerometer prediction equations (22, 32, 33), and the reference standard of 
measured EE from indirect calorimetry using an Intra Class Correlation Coefficient (ICC) 
with 95% confidence interval calculated separately for the Actigraph and Actical. 
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According to de Vet et. al, criterion validity is defined as, ‘the degree to which scores of a 
new measurement device agree with the scores of a gold standard’ (13) and criterion 
validity may be assessed by intraclass correlation coefficients when the scores are 
expressed in the same units (13). The level of agreement between scores of the 
instrument (in our case existing EE prediction equations) and the scores (EE) derived 
from the gold standard (indirect calorimetry) allows one to determine if the new 
instrument is a suitable substitute for the old(7). An ICC of 0.61–0.80 was selected a 
priori to indicate substantial agreement while an ICC >0.8 indicated excellent agreement 
(30). Equations that were used to calculate predicted energy expenditure included those 
of: Puyau et al.(32) for the Actical accelerometer and  Corder et al. (11) , Freedson et 
al.(22) and Puyau et al. (33)for the Actigraph accelerometer.  Evenson et al. (19) do not 
provide EE prediction equations in their calibration study, however, cut points from their 
study come with the strongest recommendation for use in healthy children (44).  In order 
to assess classification accuracy (sensitivity and specificity), our disease specific cut 
points were compared to those of Evenson et al. (19).  
Exploratory analyses to develop new prediction equations to estimate metabolic 
equivalents (METs) were conducted using mixed regression modelling (also referred to 
as Cross Sectional Times Series analysis) (9, 49) using SAS 9.3 (SAS Inc., Cary, N.C). 
This method is better able to handle correlated data (the same outcome, energy 
expenditure, was measured multiple times across different tasks for each subject). 
Accelerometer counts were log transformed to normalize their distribution. 
Accelerometer counts of zero were modelled separately in our model such that a zero 
count was recognized as being equivalent to REE. Explanatory variables selected a priori 
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were added to the models in a stepwise fashion to determine which contributed to the best 
fit.  Each model was evaluated using four model fitting approaches, comprising the Intra 
Class Correlation Coefficient (ICC), Akaike information criterion (AIC), Bayesian 
information criterion (BIC) and the standard error of the predicted value.  A model with 
an ICC of >0.8 indicated excellent fit, and an ICC range of 0.61-0.80 indicated good fit. 
Limits of agreement were also calculated. Additionally, paired t-tests with Bonferroni 
correction for multiple testing were preformed to ensure that EE determined from the 
new prediction equations were not different from the measured EE.  
In order to determine how well our new prediction equations might predict energy 
expenditure outside of our sample we conducted a cross-validation using the leave one 
out technique(1). Mean absolute error and root mean squared error were calculated in 
order to evaluate the prediction error around our new equations. 
 Finally, cut points establishing the relationship between accelerometer counts and 
physical activity level, were determined using Receiver Operating curve (ROC) analysis 
with Prismlab 6.3 (Graphpad Software,Inc).  Cut point thresholds that exhibited the best 
sensitivity and specificity for establishing sedentary, light, moderate and vigorous 
physical activity levels were determined. 
Results 
A total of 196 subjects were enrolled into the study; 1 subject dropped out prior to testing 
due to time constraints.   Fifteen children with CHD, 32 CF, 31 JDM, 31 JIA, 30 IMD, 28 
HE and 29 healthy subjects completed the study.  Demographic information along with 
subjective ratings of physical function, pain, illness and quality of life for healthy and 
  
12 
chronically ill subjects is presented in Table 1.  Twenty-four of the 195 children 
underwent the low-function group protocol: 1 CF, 4 JDM, 1 JIA, 4 HE, 13 IMD, and no 
CHD subjects. One healthy control also underwent the low function protocol as a result 
of a slow pacing during the 6-minute self-selected walking task.  The CHAQ resulted in 
an overall ranking of mild disability for subjects with CF, HE, JA and JDM; mild to 
moderate disability for the IMD subjects; and no disability in subjects with CHD or 
healthy controls (14). Ratings of pain and illness were highest amongst the JA group.  
Subjects with CF reported that they had the worst overall health and IMD subjects 
reported the worst overall quality of life in comparison to other disease groups and 
healthy controls (See Table 1 for further results).  
 Those with a chronic disease had higher oxygen uptake across all of the tasks combined 
in comparison with healthy controls (ANOVA; F(6, 55) = 17.0, p<0.0001).  The mean 
difference in oxygen uptake between the diseased subjects and healthy controls was 2 
ml/kg/min with a range of 0.5 to 3 ml/kg/min. All disease classifications with the 
exception of the JDM group had energy expenditures that were significantly different 
from healthy controls. Mean VO2 from the indirect calorimeter is plotted by physical task 
and by diagnosis in Figure 1.   
Accelerometer counts differed amongst the disease groups as well as between the healthy 
controls with a mean difference across all tasks combined of 22 counts for both the 
Actical and Actigraph   (range -8 to 89 counts). A significant difference in mean counts 
by diagnosis and task was found (ANOVA; F(13, 55)= 134, p<0.0001).  Figure 2 illustrates 
the difference in mean accelerometer counts (Actigraph) by diagnosis across the physical 
tasks. 
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 Agreement between the measured and predicted EE determined by an ICC and the 95% 
confidence interval around the ICC for Actical and Actigraph are presented in Table 2. 
Overall, when compared to measured, prediction equations for both the Actigraph and 
Actical resulted in poor to moderate agreement in the disease groups.  The Puyau et al.  
equation (32) developed for the Actical resulted in better overall agreement than those for 
the Actigraph with the best performance in the CHD, HE and healthy groups.  The 
Freedson equation (22) developed for the Actigraph 7124 had the best agreement across 
the disease groups in comparison to the other tested equations using the Actigraph.  
 Six disease specific equations were developed based on a significant interaction term 
between diagnosis and accelerometer count (F(6,171) = 4.3, p< 0.0005) indicating that the 
relationship between counts and EE differed depending on diagnosis. All of the disease 
models included a random effect for the intercept and accelerometer count.  Overall each 
of the disease specific models had an ICC value between 0.62-0.88 indicating good to 
excellent model fit.  No significant differences between measured and predicted EE were 
found for any of the disease specific equations with the exception of the Actical equation 
that included heart-rate for IMD subjects (See results in Table 3).  
Models that included heart rate in the prediction equation resulted in improved model fit 
and lower standard errors than prediction equations without heart rate. However, our 
disease specific prediction equations without heart rate still resulted in better agreement 
(ICC range 0.62-0.85) than the non-disease specific equations (ICC range 0.22-0.46) (see 
Supplemental Table 1 for disease specific ICC’s and standard errors).  
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Results from our leave one out cross-validation suggest good prediction precision of our 
new equations.  Generally prediction precision was similar across devices and disease 
groups with mean absolute errors ranging from 0.50 to 0.70; exceptions to this were CHD 
and JDM groups on using the Actigraph, which had poorer prediction precision (mean 
absolute error, 0.80 and 0.84, respectively). See Supplemental Table 2 for further cross-
validation results.  
Final regressions for Actigraph and Actical are presented both with heart-rate included 
and excluded by disease group (Table 3).  Heart-rate was included in order to address 
clinical user groups who will use combined methods for determining energy expenditure. 
The prediction equations along with their limits of agreement are presented in Table 3. 
 ROC curve analysis results for sedentary, light, moderate, and vigorous intensity cut-
points are presented in Table 4 for the Actigraph and Actical.  The area under the curve 
ranged from 0.82 to 0.95 for Actical and 0.80 to 0.90 for Actigraph across the four 
intensity thresholds for all chronic diseases.  Area under the curve and cut point results 
for individual disease groups are also presented in Table 4.  
Evenson et al.(19) cut points were applied to our disease groups and resulted in similar 
specificity to our disease specific cut points.  The sensitivity of the cut points were 
similar for sedentary activity but less than our disease specific cut points at higher levels 
of intensity.  Further results are summarized in Supplemental Table 3.  
 
Discussion 
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The findings of this study suggest that current prediction equations used to transform 
accelerometer counts into EE units are not accurate for children with chronic illnesses, 
since the level of agreement was low to moderate (Table 2).  Moreover, the agreement 
between predicted and measured EE was also only moderate in our healthy control group. 
 We found that EE and accelerometer counts differ across the different disease groups 
and in comparison to healthy controls (Figure 1 and 2).  Differences in EE and 
accelerometer counts could be attributed to factors related to disease pathophysiology, 
sequelae, and drug treatment (42, 43).  For example, mechanical efficiency due to joint 
damage or contractures or muscle atrophy from medication and muscle disuse in JA or 
JDM (23, 42); decreased lung function in CF (36) and disturbed muscle metabolism in 
IMD as well as deconditioning or poor neuromotor control may explain the differences in 
patterns of movement and increased energy cost of performing physical activities(8, 24). 
These differences likely explain the poor agreement using current prediction equations in 
our clinical populations. In a validation study of 34 adults with coronary artery disease 
poor agreement between predicted and measured EE using the Actigraph (7164) was also 
reported (18).  The authors cited deconditioning and limits to functional capacity as one 
of the potential factors that contributed to the poor agreement of the prediction equations 
(18). 
 The current prediction equations resulted in a moderate level of agreement in subjects 
with HE and CHD. These groups may be more similar to healthy controls.  Subjects with 
CHD in our study sample reported no disability and differences between our CHD and 
healthy controls may not have been evident due to the submaximal nature of our 
protocol(5). Recently, it has been reported that children who have undergone a Fontan 
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procedure have an enhanced submaximal work capacity (lower EE) in comparison to 
their healthy peers, and that differences in oxygen uptake are only evident at a peak 
workloads(5). The main sequelae of HE are related to the inability to produce clotting 
factor. The joint contractures and sequelae historically due to repeated significant bleeds 
have been largely eliminated in stable and well-managed North American and North 
Western European subjects with the advent of prophylactically replaced factor VIII and 
VIIII.   
A moderate level of agreement was also found using the current equations in our healthy 
controls. Our findings in the healthy group are in agreement with those published in the 
literature(3, 45). These studies also tested the validity of our selected published 
regression equations for the Actigraph and Actical and found that the accuracy of the 
equations was dependent on the type and intensity of the physical activity (3, 45).  For 
example, Alhassan et al. found that the Freedson equation used for the Actigraph 7164 
tended to overestimate high intensity activities in their sample of healthy children by as 
much as 26%, but was accurate for slow walking (3). The same group reported that the 
regression equation developed by Puyau et al, for the Actical underestimated EE across 
all activities (3, 45).  There are several explanations for the moderate level of agreement 
found in our healthy subjects.  A lack of substantial agreement could be due to 
differences in biological and physiological characteristics of our sample population or 
differences in protocols. It is possible that small validation samples in addition to subject 
selection pools may account for some of the lack of agreement in EE in our healthy 
control group.  For example, a relatively small sample size was used to develop the 
original prediction equations and may make it difficult to capture the vast variability in 
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EE in a different population (3). Biological characteristics of the study population such as 
age of the study participants may also account for some of the differences. Age ranges 
were similar in our protocol to that of Freedson’s group (age range  6 to 18) but differed 
from that of Puyau (age range  10 to 14)(3, 22, 45). Differences in the protocols used to 
develop the regression equations for the Actigraph also differed in our study as compared 
to Freedson’s as activities of daily living were not included in the original Freedson 
validation protocol (22).  
An exploratory analysis was conducted to address the need for more accurate EE 
prediction equations for children with chronic conditions. A new prediction equation was 
not developed for healthy children as much work has already been completed in this area 
with recent advances in regression modelling including time-series models, branched and 
2 regression models demonstrating promising accuracy in this cohort (9, 12, 49) Our new 
disease specific models exhibited good to excellent model fit as assessed by ICC, low 
standard errors around the predicted value, and good precision accuracy determined by 
our cross-validation.   
Our disease specific prediction equations were not significantly different from measured 
with one exception. A significant difference was found between measured and predicted 
EE for the IMD equation this finding may be by chance alone or could represent a true 
difference. The EE between predicted and measured was statistically different, however, 
this equation demonstrated good agreement, small mean differences, limits of agreement 
and standard errors, suggesting good clinical relevance. 
 In order to address the finding of a significantly different accelerometer counts across the 
physical tasks between disease conditions and also with healthy controls we developed 
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new cut-point thresholds.  ROC curve analysis was conducted to determine cut-point 
thresholds for light, moderate and vigorous physical activity for each disease group. The 
overall area under the curve for all chronic diseases demonstrated moderate to excellent 
sensitivity and specificity. The classification accuracy of our equations is similar to 
findings using the same devices in the healthy population (3, 45). In their studies good 
classification was shown for identifying vigorous levels of physical activity with 
moderate to good classification accuracy for light activities and vigorous activities (3, 
45).  
The classification accuracy of our cut points performed better than those of Evenson et 
al., which are often recommended for determining intensity thresholds in healthy 
children. While the specificity of the Evenson cut points were similar to that of the 
disease specific cut points, the sensitivity (false-negative rate) was better in our disease 
specific cut points.  Overall, this suggests that cut points recommended for healthy 
children would result in misclassification of moderate and vigorous physical activity as 
light or sedentary in children with a chronic condition.  
Our results must be considered in the context of some potential limitations in our design.  
We looked at widely used prediction equations to derive EE from both the Actigraph and 
Actical accelerometer; it is possible that a different prediction equation might provide 
better agreement for children with chronic disease.  However – it is unlikely that any 
prediction equation derived from healthy children would provide good accuracy; we have 
found a significant interaction between accelerometer counts and diagnosis that suggests 
that the relationship between accelerometer counts and EE is different in children with 
chronic conditions as compared to healthy controls and when compared to other disease 
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groups (43). As an example, in our previous study we tested the validity of the Actiheart 
accelerometer in the same population and found that a newly developed prediction 
equation tended to over-estimate energy expenditure in our chronic disease group(43).  
We performed exploratory analyses to develop six disease specific prediction equations. 
While we used diagnosis as a means to break apart the prediction equations it is possible 
that diagnosis is actually representative of some other factor (so far unmeasured) that 
could also explain the differences found between these groups. Our findings suggest that 
disease specific energy expenditure equations and cut points perform better than those 
developed in healthy children. This could be because children with a chronic disease are 
actually different from healthy children or the equations and cut points work better 
because we have optimized them for our sample. While we encourage the use of these 
equations in preference to ones developed in the healthy population, further external 
cross validation work is required.   
There are several strengths to our modelling approach that may overcome the limitations 
of other approaches. This type of modelling approach  (sometimes referred to as cross-
sectional time series analysis) (9, 49) has been used successfully in healthy cohorts and 
has shown great accuracy in predicting energy expenditure with reported mean percent 
errors ranging from ±7.4 to 10.8 and correlation concordance coefficients ranging from 
0.91 to 0.93 indicating near perfect agreement between measured and predicted energy 
expenditure(9, 49). The use of a mixed model using random coefficients better accounts 
for the correlation between EE present when a subject repeats physical tasks and may be 
used to better understand how well the modelled prediction will account for the variance 
in EE in the larger population (49). Also, we included all data points in our models rather 
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than averaged data.  Steady state data is often used to model prediction equations, but 
may not properly represent what actually occurs in the field when determining EE.  This 
approach is supported by the findings of others who have presented models that have 
improved performance when determining EE by using full signals(12, 49). Our leave one 
out cross-validation further supports the accuracy of the proposed prediction equations. 
Finally, we have provided cut-points for establishing physical activity level by disease 
group and accelerometer type that have shown good to excellent predictive capabilities. 
In conclusion, our study has shown that current prediction equations used to determine 
EE from the Actical and Actigraph accelerometers are not valid in children with chronic 
conditions.  We have completed preliminary work to develop six disease-specific 
prediction equations that have been shown to have good to excellent model fit and low 
standard errors around predicted METS. Further, we have shown good prediction 
accuracy of our prediction equations using a leave one out cross validation. We have also 
provided disease specific cut point values for the Actical and Actigraph for establishing 
physical activity levels. Future work should concentrate on confirming these equations 
and cut point values in other cohorts of children with chronic conditions and using them 
to establish relationships with health outcomes. 
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 Table 1: Descriptive characteristics of subjects, by disease category 
CF = Cystic Fibrosis; CHD = Congenital Heart Disease; HE = Hemophilia; IMD = Inherited Muscle 
disease; JDM = Juvenile Dermatomyositis; JA = Juvenile Arthritis; CHAQ_DI = Child health Assessment 
Questionnaire; PedsQL= Pediatric Quality of Life Questionnaire; SD= standard deviation 
 
 
Characteristic CF 
 
CHD HE IMD JDM JA Healthy  
Age, years        
Mean ±SD  12.8 ± 2.9  13.6 ±3.3  12.4±3.3  12±3.4 13.4±2.3 12.7±2.6 13.1 ± 2.8  
Gender, n (%)        
Male 18(56) 10(67) 28(100) 22(73) 11(35) 8(26) 16 (55) 
Female 14(44) 5(33) 0 (0) 8(27) 20(65) 23(74) 13 (45) 
Height, cm        
Mean ±SD  156 ± 16  161 ±17  156±19 146±22  159±11 154±12 162 ± 16  
Weight, kg        
Mean ±SD  45 ± 14  54±17  53±20.7  41±14 52±14 47±14 57.6 ± 20  
BMI percentile 
% Underweight <5% 
3% 7% 4% 7% 10% 16% 0% 
% Overweight 85-95% 0% 27% 29% 17% 13% 16% 28% 
% Obese >95% 3% 7% 7% 7% 10% 3% 0% 
Sum of Skinfold, mm        
Mean± SD  31 ± 13  42±15.5  40±20  41±18 48±17 46±22 38 ± 17  
Tanner Stage (%)        
Prepubescent 
(Stages 1,2) 
19% 38% 27% 70% 27% 32% 30% 
Pubescent 
(Stages ≥ 3) 
 
81% 62% 73% 30% 73% 68% 70% 
CHAQ Total Score 0.27±0.3 0.17± 0.3 0.25 ±0.4 0.80 ±0.7 0.40 ±0.6 0.50 ±0.5 0.15±0.26 
 
CHAQ Pain  0.6 ±0.9 0.2 ±0.6 1.0 ±1.7 1.5 ±1.8 1.4 ±2.1 2.6 ±3 1.3± 1 
 
CHAQ Overall Health  2.1 ±2.8 0.4 ±0.6 0.5 ±1.3 1.5 ±2 1.2 ±1.7 1.9 ±2.4 1.3 ± 2 
CHAQ Illness 1.8 ±1.9 0.6 ±1.3 0.7 ±1.4 2.0 ±2.4 2.0 ±2.1 2.1 ±2 1.3 ± 2 
 
PedsQL Total Score 78 ±12 72 ±12  82 ±16 68 ±17 77 ±15 72 ±13 83±9 
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Table 2:  Agreement Between Predicted and Measured AEE by Diagnosis  
Diagnosis 
Actical ICC (2,1)  (95% CI) 
 
Actigraph ICC (2,1)  (95% CI) 
 
Puyau et. al Corder et. al Freedson et. al Puyau et. al 
Chronic Illness 
(combined) 0.40 (0.35-0.45) 
0.26 (0.20-0.30) 0.32(0.30-0.40) 0.21(0.10-0.30) 
  CF 0.39 (0.27-0.50) 0.28 (0.14-0.40) 0.36 (0.23-0.48) 0.21(0.09-0.30) 
CHD 0.43 (0.27-0.58) 0.26 (0.03-0.50) 0.35 (0.08-0.58) 0.20 (0.00-0.63) 
HE 0.46 (0.36-0.58) 0.26 (0.14-0.39) 0.35 (0.22-0.46) 0.21 (0.08-0.36) 
IMD 0.38 (0.25-0.50) 0.31 (0.17-0.45) 0.36 (0.21-0.49) 0.25 (0.10-0.39) 
JDM 0.34 (0.21-0.45) 0.17 (0.00-0.33) 0.18 (0.02-0.34) 0.13 (0.00-0.30) 
JA 0.41 (0.30-0.52) 0.28 (0.14-0.40) 0.35 (0.22-0.47) 0.22 (0.09-0.35) 
Healthy 0.41 (0.30-0.52) 0.30 (0.20-0.40) 0.39 (0.30-0.50) 0.23 (0.10-0.40) 
 
CF = Cystic Fibrosis; CHD = Congenital Heart Disease; HE = Hemophilia; IMD = Inherited Muscle Disease;  
JDM =Juvenile Dermatomyostis; JA = Juvenile Arthritis. 
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Table 3: Disease Specific Prediction Equations. Two prediction equations are presented for each type of Accelerometer (Actical or Actigraph) one 
equation with Heart-Rate and one equation without Heart-Rate for Estimating METs. 
Diagnosis Prediction Equation Limits of Agreement 
Mean difference (lower 
and upper bounds)  
Paired 
Difference 
T-value (P-
value) 
Device 
CF METs = - 3.3 – 0.07(zero counts) + 0.52×log (counts+100) + 0.026(heart rate) -0.01 (-1.5 to 1.5) -1.2 (0.24) Actigraph 
 METs = - 2.7– 0.4075(zero counts) + 0.9074×log (counts+100) -0.06 (-1.7 to 1.5) 2.3 (0.01) Actigraph 
 METs= - 3.2 - 0.0815(zero counts) + 0.4384×log(counts+100) + 0.03(heart 
rate) 
-0.004 (-1.5 to 1.6) -0.51 (0.61) Actical 
 METs = - 2.4 – 0.5(zero counts) + 0.9×log(counts+100) -0.00 (-1.8 to 1.8) 0 (0.99) Actical 
CHD METs = - 3.5 – 0.54(zero counts) + 0.83×log (counts+100) + 0.015(heart rate) -0.04 (-2.0 to 1.9) 1.7 (0.09) Actigraph 
 METs = - 2.87 – 0.84(zero counts) + 1.02×log (counts +100) -0.006 (-2.2 to 2.2) -0.30 (0.77) Actigraph 
 METs = - 3.68 - 0.3154(zero counts) + 0.7892×log(counts+100) + 0.018(heart 
rate) 
0.01 (-1.5 to 1.6) 1.1 (0.26) Actical 
 METs = - 3.5 – 0.5(zero counts) +1.1×log(counts+100) 0.01 (-1.6 to 1.6) 0.88 (0.38) Actical 
HE METs = -3.81 - 0.2824 (zero counts) + 0.8396×log (counts+100) + 
0.01692(heart rate) 
-0.01 (-1.3 to 1.3) -1.9 (0.06) Actigraph 
 METs = -3.62- 0.496 (zero counts) + 1.11×log (counts+100) -0.01 (-1.4 to 1.4) -1.5 (0.14) Actigraph 
 METs= -4.0 – 0.3424(zero counts) + 0.8569×log(counts+100)+0.01989(heart 
rate) 
-0.02 (-1.5 to 1.5) -1.2 (0.06) Actical 
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 METs = - 3.55 – 0.69(zero counts) + 1.15×log(counts+100) -0.01 (-1.7 to 1.7) -1.4 (0.16) Actical 
IMD METs = - 2.4 – 0.02933(zero counts) + 0.3044×log(counts+100) + 
0.02652(heart rate) 
0.60 (-1.0 to 2.2) 2.4 (0.02) Actigraph 
 METs = - 2.1 – 0.1753(zero counts) +0.7552×log(counts+100) 0.09 (-1.4 to 1.5) 1.3, (0.19) Actigraph 
 METs = - 3.1 – 0.06421(zero counts) 
+0.3975×log(counts+100)+0.02731(heart rate) 
0.08 (-1.2 to 1.4) 11.0, <0.0001* Actical 
 METs = - 3.9 -0.05573(zero counts) +1.112×log(counts+100) -0.08 (-1.5 to 1.3) 1.3, 0.17 Actical 
JA METs = - 3.1138 + 0.1745(zero counts) + 0.276×log(counts+100) 
+0.041(heart rate) 
0.01 (-1.7 to 1.7) 1.2 (0.24) Actigraph 
 METs = - 1.8 – 1.0 (zero counts) + 0.8462×log(counts+100) 0.09 (-2.1 to 2.3) 0.45 (0.65) Actigraph 
 METs = - 3.64 -0.0879(zero counts) +0.041×log(counts+100)+ 0.03883(heart 
rate) 
0.004 (-1.7 to 1.7) 0.41 (0.68) Actical 
 METs = - 3.4 – 1.1(zero counts) +0.85×log (counts+100) 0.01 (-1.9 to 1.9) -0.95 (0.34) Actical 
JDM METs = - 3.0 – 0.5089(zero counts) + 0.4797×log(counts+100) + 
0.02821(heart rate) 
0.006 (-2.2 to 2.2) 1.7 (0.08) Actigraph 
 METs = - 2.0 – 0.3(zero counts) + 1.1×log(counts+100) -0.002 (-2.2 to 2.2) -0.13 (0.89) Actigraph 
 METS= - 4.3 -0.13(zero counts) +0.7148×log(counts+100) + 
0.02678(heartrate)  
0.004 (-1.8 to 1.8) 0.36 (0.72) Actical 
 METS = - 3.9 – 0.47(zero counts) +1.18×log(counts+100) -0.003 (-1.8 to 1.8) -0.35 (0.72) Actical 
CF = Cystic Fibrosis; CHD = Congenital Heart Disease; HE= Hemophilia; IMD=Inherited Muscle Disease; JA = Juvenile Arthritis; JDM = Juvenile 
Dermatomyositis. * Denotes significance at p < 0.0002 level after adjustment using Bonferroni correction for multiple tests. 
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Table 4: Cut points for Actigraph and Actical Accelerometer by Diagnosis 
 Actigraph Actical  
Diagnosis Intensity* AUC (95%CI) Sensitivity % 
Specificity
% Cut point AUC (95%CI) 
Sensitivity 
% 
Specificity
% Cut point 
Chronic 
Disease 
(combined) 
Sedentary 0.81 (0.77-0.85) 71 96 < 10 0.88 (0.86-0.90) 77 94 < 10 
Light NA NA NA >10 -426 NA NA NA >17-288 
Moderate 0.80 (0.77-0.83) 70 81 >426-784 0.82 (0.80-0.85) 72 78 >289-569 
Vigorous 0.86 (0.79-0.94) 87 84 >785 0.95 (0.92-0.97) 92 87 >570 
CF 
Sedentary 0.90 (0.84-0.95) 77 98 <10 0.86 (0.80-0.92) 74 95 < 5 
Light NA NA NA >10 -487 NA NA NA >5-368 
Moderate 0.88 (0.83-0.93) 83 81 >487-852 0.79 (0.72-0.86) 70 78 >368-1025 
Vigorous 0.91 (0.86-0.96) 100 88 >853 0.98 (0.96-1.0) 100 98 >1025 
CHD 
Sedentary 0.99 (0.99-1.0) 92 97 <10 0.99 (0.99-1.0) 100 98 <9 
Light NA NA NA >10-349 NA NA NA >9-349 
Moderate 0.82 (0.71-0.93) 85 76 >349-785 0.87 (0.81-0.94) 81 83 >349-633 
Vigorous 0.81(0.61-1.0) 87 84 >785 0.95 (0.90-1.0) 100 92 >633 
HE 
Sedentary 0.97 (0.93-1.0) 90 99 <17 0.94 (0.90-1.0) 95 94 < 19 
Light NA NA NA >17-432 NA NA NA >19-306 
Moderate 0.88 (0.84-0.93) 76 87 >432-788 0.82 (0.77-0.88) 72 80 >306-1114 
Vigorous 0.93 (0.85-1.0) 100 84 >788 0.85 (0.64-1.0) 67 98 >1114 
IMD 
Sedentary 0.90(0.86-0.95) 78 91 <37 0.96 (0.93-0.98) 82 97 <14 
Light NA NA NA >37-663 NA NA NA >14-297 
Moderate 0.91(0.85-0.97) 81 94 >663-972 0.89 (0.83-0.94) 82 81 >297-523 
Vigorous 0.92 (0.88-0.96) 100 92 >972 0.91 (0.87-0.95) 100 90 >523 
JDM 
Sedentary 0.83 (0.79-0.9) 73 84 <14 0.89 (0.83-0.94) 83 92 <18 
Light NA NA NA >14-172 NA NA NA >18-166 
Moderate 0.78 (0.71-0.86) 82 66 >172-543 0.85 (0.79-0.90) 86 70 >166-601 
Vigorous 0.79 (0.52-1.0) 83 79 >543 0.96 (0.93-0.99) 100 91 >601 
JA 
Sedentary 0.82 (0.74-0.90) 75 91 <19 0.84 (0.78-0.90) 78 88 <25 
Light NA NA NA >19-152 NA NA NA >25-255 
Moderate 0.78 (0.71-0.86) 86 63 >152-542 0.82 (0.77-0.88) 72 75 >255-771 
Vigorous 0.78 (0.52-1.0) 83 79 >542 0.98 (0.96-1.0) 100 94 >771 
*Sedentary  (<1.5 METs); light (1.5-2.99 METs); moderate (3.0 - 5.99 METs); vigorous (>6.0 METs); NA = Not applicable- values were not calculated as 
sedentary and moderate provide the boundaries for the cut point thresholds. 
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Figure 1: Oxygen Uptake (ml/kg/min) Across Physical Tasks by Diagnosis 
 
 
 
 
 
 
 
 
 
Figure 2: Mean Accelerometer Count (Actigraph) Across Physical Task by Diagnosis 
 
 
 
